After an average follow-up of about 17 months, the research team found that while 73.7 percent of the gefitinib patients responded positively to their treatment, only 30.7 percent of the chemotherapy patients did so. 在随后的平均 17 个月的调查中，研究小组发现73.7%的患者对吉非替尼的治疗有积极的反应，而同时仅 30.7%的化疗病人有积极的反应。
The mean survival time with no cancer progression was significantly higher among the gefitinib group -- 10.8 months, compared to 5.4 months among the chemotherapy group. In addition, one and two-year survival rates were, respectively, 42.1 percent and 8.4 percent among those in the gefitinib group, compared to 3.2 and zero among those in the chemotherapy group. 就没有癌症进展的平均存活时间而言，吉非替尼群是10.8个月，化疗组是5.4个月，吉非替尼组要高出许多。此外，一年和两年存活率分别是，吉非替尼组 42.1%和 8.4%，而化疗组是3.2%和零。
易瑞沙、特罗凯、格列卫，
印度抗癌药邮购中心版权所有
。官方网址：www.india-anticancer.com
|
